# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.
DSMB Recommends Continuation without Modification for Third TimeSafety Review Included 395 PatientsInterim Survival Analysis St...
HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.
HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.
InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.22) by 15...
HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.